MJMarni B. Jacobs

Marni B. Jacobs

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marni B. Jacobs has a total of 355 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Disparities in low‐dose aspirin prescription among patients at risk for preeclampsia

    by Daniella Rogerson, Carolina Thorlund‐Díaz, Marni Jacobs, Emily Harnois, Lillian Blank, Leilani Gutierrez‐Palominos, Ayelet Ruppin‐Pham, Maryam Tarsa, E. Nicole Teal

    Objective: Low‐dose aspirin (LDA) reduces preeclampsia risk, yet prescribing rates among eligible pregnant patients remain low. This study aims to determine whether there are disparities in LDA prescription to eligible patients based on race/ethnicity, primary language, or insurance after implementation of a standardized electronic health record (EHR) preeclampsia risk screening tool. Study design: This retrospective cohort study included all patients ≥ age 18 with births at a single academic center from September 2022 to July 2025 who had 1 high or ≥2 moderate preeclampsia risk factors. The primary outcome was rate of LDA recommendation/prescription, determined by recommendation documentation in the risk screening tool or prescription in the EHR medication log. Data were extracted from Epic Clinical Data Warehouse. Chi‐square or t ‐tests were used to compare LDA prescribing rates by race/ethnicity, primary language, and insurance, and multivariable regression models were used. Results: Of 5737 LDA‐eligible patients, 3995 (69.6%) were recommended/prescribed LDA and 1742 (30.4%) were not. Patients recommended/prescribed LDA were more likely to be older, multiparous, English speaking, and privately insured and/or have pregestational diabetes or chronic hypertension, as well as high‐risk factors for preeclampsia ( p < 0.001). In an adjusted multivariable analysis for age, race, parity, body mass index, language, diabetes mellitus, chronic hypertension [cHTN], and insurance type, Black/African American patients (adjusted OR [aOR] 1.80, 95% confidence interval [CI] 1.36–2.39) and patients with high‐risk factors for preeclampsia (aOR 2.66, 95% CI 2.14–3.31) had higher odds of being prescribed/recommended LDA while non‐English speaking (Spanish aOR 0.60, 95% CI 0.46–0.78; another language aOR 0.62, 95% CI 0.45–0.85) and publicly insured (aOR 0.80, 95% CI 0.69–0.93) patients had lower odds. Differences in prescription/recommendations by race and insurance were primarily driven by those with moderate risk factors for preeclampsia, while this was not true for differences in prescription for non‐English speaking patients. Conclusions: After implementation of a standardized preeclampsia risk screening tool, LDA was more often prescribed to eligible Black patients than White, likely reflecting ACOG's inclusion of Black race as a proxy for racism as a preeclampsia risk factor. However, LDA was less often prescribed to publicly insured or non‐English speaking patients, which highlights an opportunity for quality and equity improvement.

  • Determinants of Placental Versus Maternal Preeclampsia

    by Omonigho Aisagbonhi, Marni B. Jacobs, Morgan Meads, Valentina Stanley, Leah M. Lamale-Smith, Ukachi N. Emeruwa, Louise C. Laurent, Kathleen M. Fisch, Mariko Horii

    BACKGROUND: The placenta is known to be critical in the etiology of preeclampsia. However, there is a subset of preeclampsia cases without identifiable placental pathology. We evaluated which clinical preeclampsia classification system best distinguishes preeclampsia with placental pathology from preeclampsia without placental pathology. METHODS: We evaluated 5 placental pathological features in 197 placentas from patients with preeclampsia grouped by 3 clinical preeclampsia subclasses: (1) preeclampsia with calculated infant birthweight P <0.0001). SGA preeclampsia and SGA normotensive placentas were abnormal and shared alterations in hypoxia, TNFα (tumor necrosis factor alpha), glycolysis, unfolded protein response, estrogen response, ultraviolet response, p53, TGFβ (transforming growth factor beta), and mTORC1 (mammalian target of rapamycin complex 1) signaling pathways. CONCLUSIONS: Classifying preeclampsia based on birthweight percentile for gestational age is the most useful system for consistently identifying preeclampsia associated with placental pathology.


  • Clinical and Molecular Differences of Hypertensive Disorders During Pregnancy

    by Mariko Horii, Robert Morey, Jennifer N. Chousal, Anushka Edlabadkar, Abbas Hakim, Tzu Ning Liu, Morgan Meads, Valentina Stanley, Samantha La Belle, Sierra Adkins, et al.

    BACKGROUND: Hypertensive disorders of pregnancy (HDP) comprise a spectrum of 4 subtypes: chronic hypertension (cHTN), gestational hypertension (gHTN), preeclampsia (PE), and superimposed preeclampsia (siPE). Although often characterized as a spectrum of disease severity, there have been limited comparative studies of detailed clinical and molecular characteristics of these disorders. We hereby evaluate HDP subtypes using clinical, placental histopathologic, and molecular data to compare similarities and differences between HDP subtypes. METHODS: We used data from an over 10-year-long pregnancy cohort with detailed clinical and placental pathology, as well as placental tissue RNA-sequencing, to compare findings between HDP subtypes using a nested case-control design. Clinical diagnosis was based on current ACOG criteria, and placental gross and histological examination was based on the Amsterdam consensus statement. RESULTS: Clinical data analysis showed cHTN and gHTN to be more likely to have normal placental pathology, while PE and siPE were more enriched in maternal vascular malperfusion. RNA-seq showed distinct gene expression signatures and pathway activation across HDP subgroups. We could not identify any molecular evidence that preeclampsia (PE or siPE) was an advanced stage of hypertensive disorder (gHTN or cHTN), but rather identified distinct gene expression profiles between these entities, suggesting preeclampsia (PE or siPE) and hypertension (gHTN or cHTN) are distinct pathophysiological conditions. Finally, we found that, in the presence of maternal vascular malperfusion, PE and siPE share significant gene expression profiles and pathway activation. CONCLUSIONS: Our findings suggest that maternal vascular malperfusion specifically differentiates pregnancies that progress to PE and siPE. Maternal vascular malperfusion is thought to initiate in early gestation, indicating the cascade to PE/siPE may be differentiated from gHTN/cHTN early in pregnancy. Incorporating placental histopathologic evaluation is an essential future avenue in probing the etiology of HDP.


  • Open Access

    Feasibility of implementing a standardized preeclampsia risk screening tool into the electronic medical record

    by Daniella Rogerson, Carolina Thorlund‐Díaz, Marni B. Jacobs, Lillian Blank, Omar Mesina, Ayelet Ruppin‐Pham, Maryam Tarsa, Cynthia Gyamfi‐Bannerman, E. Nicole Teal

    Background: Despite the fact that low‐dose aspirin (LDA) is the only effective intervention for preeclampsia risk reduction, not all those at increased risk of preeclampsia are recommended it. This study examines feasibility of implementing a preeclampsia risk screening tool into the electronic health record (EHR) to prompt LDA recommendation when appropriate and assesses whether there are differences in screening rates by race/ethnicity, language, or insurance payor. Methods: A standardized preeclampsia risk screening tool was launched in September 2022, which was intended to be used for all obstetrical patients to assess LDA eligibility. To assess feasibility of this tool, we conducted a retrospective cohort study of patients who delivered at an academic medical center from July 2023 to June 2024. The primary outcome of this was feasibility, defined as percentage of patients who delivered each month who had been screened using the tool. The secondary outcome was association between sociodemographic characteristics and screening. Chi‐square and Student's t ‐tests were used to compare characteristics between screened status, and multivariable logistic regression determined strength of association. Logistic regression was used to determine differences in screening rates over each month. Results: A total of 4556 patients met inclusion criteria, and 2521 (55.3%) were screened using the tool. Tool use increased from 46.2% in the first month to 67.4% in the last month of the study, with the odds of the tool being used increasing on average 7% per month over 1 year ( p < 0.05). Compared to patients who identify as Non‐Hispanic White, patients who identify as Hispanic/Latino had lower odds of being screened when adjusting for ethnicity/race, language, insurance, body mass index (BMI), and age (adjusted odds ration [aOR], 0.75; 95% confidence interval [CI], 0.62–0.89). In the same adjusted analysis, non‐English speaking patients were less likely to be screened than English‐speaking (aOR, 0.51; 95% CI, 0.36–0.71 and aOR, 0.51; 95% CI, 0.36–0.73) and publicly insured patients were less likely to be screened than privately insured (aOR, 0.83; 95% CI, 0.72–0.97). Conclusions: Preeclampsia risk screening increased substantially after implementing this standardized tool into the EHR which demonstrates its feasibility. We observed disparities in screening rates by race/ethnicity, language, and insurance payor.


  • Antibody Levels From High-Throughput Variant-Specific SARS-CoV-2 Anti-Spike Immunoglobulin G and Angiotensin-Converting Enzyme 2 Neutralization Assays Correlate With COVID-19 Infection Risk in a Large Population

    by Marni B Jacobs, Alex E Clark, Nicole H Goldhaber, Holly D Valentine, Andrea Rivera, Toan Ngo, Tom Barber, Jacqueline Holmes, Brittany Manfredi, Aaron F Garretson, et al.

    Background: SARS-CoV-2 antibody levels have been proposed as a correlate of protection from infection. Yet, large-scale prospective studies of cost-effective scalable antibody measures as predictors of infection under real-world conditions are limited. We examined whether antibody levels measured by high-throughput variant-specific SARS-CoV-2 anti-spike immunoglobulin G (IgG) and angiotensin-converting enzyme 2 (ACE2) neutralization assays correlate with cell-based neutralizing antibody measurements and whether they can serve as a reasonable correlate of protection from SARS-CoV-2 infection. Methods: We conducted a large institutional cohort study between January 2022 and March 2023. Participants (N = 2513) provided dried blood spot (DBS) samples for assessment of anti-spike IgG and ACE2 inhibition levels through high-throughput assays. Comparison with authentic cell-based SARS-CoV-2 neutralizing antibody assays was conducted with serum samples (n = 105). Associations between antibody levels and risk of infection were evaluated. Results: Correlation between serum and DBS sampling and between cell-based neutralizing and high-throughput antibody binding assays was high for anti-spike IgG and ACE2 neutralization, though the degree of correlation varied by variant. Longitudinal evaluation suggested that DBS-based IgG and ACE2 inhibition levels were anticorrelated with infection risk, with higher sensitivity noted for ACE2 inhibition and variant-matched measures. IgG and ACE2 inhibition levels decreased over time, with more durable responses observed in participants whose most recent priming event was infection vs vaccination. Conclusions: Findings suggest that variant-specific SARS-CoV-2 antibody levels may be a useful correlate of protection for infection, which has important implications for vaccination recommendations and evaluating infection risk. High-throughput assays measured via DBS may have utility in timing of boosters at the population or individual level.


  • Open Access

    Longitudinal assessment of the impact of COVID-19 infection on mask-wearing behaviors

    by Danielle Pham, Angel Lomeli, Nicole H. Goldhaber, Holly D. Valentine, Rob Knight, Christopher A. Longhurst, Louise C. Laurent, Marni B. Jacobs

    Background: Wearing a mask was a crucial component in slowing the COVID-19 pandemic. However, little is known about the intersectionality between mask usage, risk perception, and infection. The purpose of this study was to investigate whether risk perceptions and masking behaviors are associated with contracting SARS-CoV-2 and how contracting SARS-CoV-2 subsequently changes masking behaviors in specific situations. Methods: This cohort study utilized survey data from the UC San Diego ZAP COVID-19 study (n = 1,230) to evaluate the risk of contracting SARS-CoV-2 in relation to baseline risk perceptions and masking behaviors in various situations and how contracting SARS-CoV-2 affects subsequent masking behavior. Results: We found that more consistent self-reported mask use in indoor public spaces (p = 0.03) and in other people’s houses (p = 0.002) was associated with remaining free of SARS-CoV-2 infection. We also found that contracting SARS-CoV-2 was associated with a subsequent increase in mask use in other people’s houses (p = 0.01). Conclusions: Our findings suggest that consistent mask use is correlated with decreased infection and that contracting SARS-CoV-2 may modify mask use behaviors in high-risk situations. These findings may help inform future public health messaging for infectious disease prevention. Trial registration: This study has not been previously registered as it is an observational study. There was no pre-registration of the analytic plan for the present study.


  • Placental pathology and fetal growth outcomes in pregnancies complicated by maternal obesity

    by Samantha Hietalati, Donna Pham, Harneet Arora, Marina Mochizuki, Gisselle Santiago, Jordan Vaught, Erika T. Lin, Karen K. Mestan, Mana Parast, Marni B. Jacobs

    Background The rising prevalence of maternal obesity presents a significant health concern because of the possible implications for obstetric complications and neonatal outcomes. Understanding the impact of obesity on placental structure and function as well as fetal growth and infant outcomes is important to improve the care of these potentially high-risk pregnancies. This study aimed to determine the effect of elevated maternal BMI on histopathologic patterns of placental injury and its consequences on fetal growth. Methods Data were collected from an ongoing cohort of maternal-infant dyads in the UCSD Obstetric Registry spanning 2011–2020. Maternal characteristics, including BMI, hypertensive disease and diabetes, placental gross and histopathology, and infant characteristics, including sex and birthweight, were recorded and analyzed. ANOVA and chi-square tests were used in initial analyses, followed by log-binomial and linear regression models adjusted for relevant confounders to determine associations between maternal BMI, specific patterns of placental injury, and infant birthweight percentiles. Results Among 1366 maternal-infant dyads, placentas from mothers with overweight and obesity were heavier and demonstrated higher adjusted relative risks of chronic villitis (CV), decidual vasculopathy, intervillous thrombosis, and normoblastemia. Placental efficiency, determined by fetal-placental weight ratio, was decreased with increasing BMI. Maternal obesity was associated with higher rates of preterm birth and higher birthweight percentiles. Multiple placental lesions, including maternal (MVM) and fetal vascular malperfusion (FVM), exhibited significant effects on birthweight percentiles; however, only MVM showed a differential effect based on maternal obesity. Conclusions Presence of obesity in pregnancy is associated with increased rates of placental patterns of injury, decreased placental efficiency, and increased birthweight percentiles. While placental lesions, such as CV, have the potential to negatively impact fetal growth, the resulting birthweight percentiles demonstrate a more complex relationship between maternal obesity and fetal growth, that likely involves placental and fetal adaptation to the altered in utero environment.


  • Differences in Cardiometabolic Proteins in Pregnancy Prioritize Relevant Targets of Preeclampsia

    by Kathryn J. Lindley, Andrew Perry, Marni Jacobs, Lauren Petty, Kaushik Amancherla, Shilin Zhao, Claire Barker, Victor G. Davila-Roman, Sadiya S. Khan, Sarah S. Osmundson, et al.

    BACKGROUND: Preeclampsia is a hypertensive disorder of pregnancy characterized by widespread vascular inflammation. It occurs frequently in pregnancy, often without known risk factors, and has high rates of maternal and fetal morbidity and mortality. Identification of biomarkers that predict preeclampsia and its cardiovascular sequelae before clinical onset, or even before pregnancy, is a critical unmet need for the prevention of adverse pregnancy outcomes. METHODS: We explored differences in cardiovascular proteomics (Olink Explore 384) in 256 diverse pregnant persons across 2 centers (26% Hispanic, 21% Black). RESULTS: We identified significant differences in plasma abundance of markers associated with angiogenesis, blood pressure, cell adhesion, inflammation, and metabolism between individuals delivering with preeclampsia and controls, some of which have not been widely described previously and are not represented in the preeclampsia placental transcriptome. While we observed a broadly similar pattern in early (<34 weeks) versus late (≥34 weeks) preeclampsia, several proteins related to hemodynamic stress, hemostasis, and immune response appeared to be more highly dysregulated in early preeclampsia relative to late preeclampsia. CONCLUSIONS: These results demonstrate the value of performing targeted proteomics using a panel of cardiovascular biomarkers to identify biomarkers relevant to preeclampsia pathophysiology and highlight the need for larger multiomic studies to define modifiable pathways of surveillance and intervention upstream to preeclampsia diagnosis.


  • Open Access

    Placental Pathology and Fetal Growth Outcomes in Pregnancies Complicated by Maternal Obesity

    by Marni Jacobs, Samantha Hietalati, Donna Pham, Harneet Arora, Marina Mochizuki, Gisselle Santiago, Jordan Vaught, Erika Lin, Karen Mestan, Mana Parast

    Background: The rising prevalence of maternal obesity presents a significant health concern because of the possible implications for obstetric complications and neonatal outcomes. Understanding the impact of obesity on placental structure and function as well as fetal growth and infant outcomes is important to improve the care of these potentially high-risk pregnancies. This study aimed to determine the effect of elevated maternal BMI on histopathologic patterns of placental injury and its consequences on fetal growth. Methods: Data were collected from an ongoing cohort of maternal-infant dyads in the UCSD Obstetric Registry spanning 2011–2020. Maternal characteristics, including BMI, hypertensive disease and diabetes, placental gross and histopathology, and infant characteristics, including sex and birthweight, were recorded and analyzed. ANOVA, chi-square tests, and log-binomial and linear regression models adjusted for relevant confounders were employed to determine associations between maternal BMI, specific patterns of placental injury, and infant birthweight percentiles. Results: Among 1366 maternal-infant dyads, placentas from overweight and obese mothers were heavier and demonstrated higher adjusted relative risks of chronic villitis (CV), decidual vasculopathy, intervillous thrombosis, and normoblastemia. Placental efficiency, determined by fetal-placental weight ratio, was decreased with increasing BMI. Maternal obesity was associated with higher rates of preterm birth and higher birthweight percentiles. Multiple placental lesions, including maternal (MVM) and fetal vascular malperfusion (FVM), exhibited significant effects on birthweight percentiles; however, only MVM showed a differential effect based on maternal obesity. Conclusions: Maternal obesity is associated with increased rates of placental patterns of injury, decreased placental efficiency, and increased birthweight percentiles. While placental lesions, such as CV, have the potential to negatively impact fetal growth, the resulting birthweight percentiles demonstrate a more complex relationship between maternal obesity and fetal growth, that likely involves placental and fetal adaptation to the altered in utero environment.

  • Associations Between Maternal Sociodemographics and Hospital Mortality in Newborns With Prenatally Diagnosed Hypoplastic Left Heart Syndrome

    by Keila N. Lopez, Shaine A. Morris, Anita Krishnan, Marni B. Jacobs, Aarti H. Bhat, Anjali Chelliah, Joanne S. Chiu, Bettina F. Cuneo, Grace Freire, Lisa K. Hornberger, et al.